Tenelit M Plus Tablet combines Metformin (500mg) and Teneligliptin (20mg), offering a dual-action antidiabetic therapy for patients with type 2 diabetes mellitus. Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, while Teneligliptin, a DPP-4 inhibitor, increases incretin levels, stimulating insulin release and suppressing glucagon secretion after meals.
This combination provides comprehensive glycemic control, targeting both fasting and postprandial blood glucose levels. It is commonly prescribed when monotherapy is insufficient or when tighter glucose regulation is needed.
Belonging to the antidiabetic and endocrinology segment, Tenelit M Plus Tablet is highly recommended by physicians for its efficacy, safety, and tolerability. It is suitable for adults requiring combination therapy and helps reduce long-term diabetic complications.
For PCD pharma franchise partners, third-party manufacturers, and exporters, Tenelit M Plus Tablet represents a high-demand product with strong business potential. Its combination therapy format makes it a profitable addition to any B2B diabetes care portfolio, catering to hospitals, clinics, and pharmacies across India.